| Literature DB >> 35580861 |
Wangyang Zheng1,2,3, Xue Bai4, Yongxu Zhou1,2, Liang Yu1,2, Daolin Ji2,5, Yuling Zheng6, Nanfeng Meng1, Hang Wang1, Ziyue Huang1, Wangming Chen1, Judy Wai Ping Yam7, Yi Xu1,2,7, Yunfu Cui1.
Abstract
Inositol 1,4,5-Triphosphate Receptor Family (ITPRs) are necessary intracellular Ca2+-release channel encoders and participate in mammalian cell physiological and pathological processes. Previous studies have suggested that ITPRs participate in tumorigenesis of multiple cancers. Nevertheless, the diverse expression profiles and prognostic significance of three ITPRs in pancreatic cancer have yet to be uncovered. In this work, we examined the expression levels and survival dates of ITPRs in patients with pancreatic cancer. As a result, we identified that ITPR1 and ITPR3 expression levels are significantly elevated in cancerous specimens. Survival data revealed that over-expression of ITPR2 and ITPR3 resulted in unfavourable overall survival and pathological stage. The multivariate Cox logistic regression analysis showed that ITPR3 could be an independent risk factor for PAAD patient survival. Moreover, to investigate how ITPRs work, co-expressed genes, alterations, protein-protein interaction, immune infiltration, methylation, and functional enrichment of ITPRs were also analyzed. Then, we evaluated these findings in clinical samples. Moreover, the gain and loss of function of ITPR3 were also conducted. The electron microscope assay was employed to explore the role of ITPR3 in pancreatic cancer cell lines' endoplasmic reticulum stress. In summary, our findings demonstrated that ITPR3 has the potential to be drug targets and biomarkers for human pancreatic cancer.Entities:
Keywords: ITPRs; bioinformatics analysis; biomarker; pancreatic cancer; therapeutic targets
Mesh:
Substances:
Year: 2022 PMID: 35580861 PMCID: PMC9186782 DOI: 10.18632/aging.204080
Source DB: PubMed Journal: Aging (Albany NY) ISSN: 1945-4589 Impact factor: 5.955
Figure 1The overview of expression of ITPRs in pan-cancer. (A) The transcription levels of ITPRs in different types of cancers (ONCOMINE). (B) The expression of ITPRs in cancer cell lines (CCLE). Result of the expression of ITPR2 in cancer cell lines (CCLE). The expression of ITPR3 in cancer cell lines (CCLE).
The significant changes of ITPRs expression in the transcriptional level between cancer and normal tissues (Oncomine database).
|
|
|
|
|
|
|
| ITPR1 | Pancreatic Carcinoma versus Normal | 1.474 | 0.030 | 2.033 | Segara [ |
| Pancreatic Ductal Adenocarcinoma vs. Normal | 1.749 | 1.36e-5 | 4.616 | Badea [ | |
| ITPR2 | Pancreatic Carcinoma versus Normal | 1.235 | 0.013 | 2.479 | Segara [ |
| ITPR3 | Pancreatic Carcinoma versus Normal | 2.462 | 3.99e-4 | 4.197 | Segara [ |
| Pancreatic Ductal Adenocarcinoma versus Normal | 1.948 | 1.12e-9 | 6.864 | Badea [ | |
| Pancreatic Adenocarcinoma versus Normal | 16.110 | 0.045 | 2.199 | Logsdon [ | |
| Pancreatic Adenocarcinoma versus Normal | 4.479 | 1.83e-7 | 8.568 | Iacobuzio-Donahue [ | |
| Pancreatic Ductal Adenocarcinoma versus Normal | 2.314 | 0.034 | 1.925 | Grutzmann [ | |
| Pancreatic Carcinoma versus Normal | 3.467 | 6.03e-8 | 6.784 | Pei [ |
Figure 2The Expression of ITPRs family in pancreatic cancer (GEPIA). (A) The Gene Expression Profiles of ITPR1, ITPR2, and ITPR3. (B) The Box plots of ITPR1, ITPR2, and ITPR3 genes Expressions.
Figure 3Prognostic value of ITPRs in pancreatic cancer. (A) The prognostic value of ITPRs in pancreatic cancer OS; (Kaplan-Meier Plotter database). (B) The prognostic value of ITPRs in pancreatic cancer RFS; (Kaplan-Meier Plotter database). (C) The prognostic value of ITPRs in pancreatic cancer staging. (GEPIA database).
Univariate and multivariate Cox logistic regression analysis of OS in The Cancer Genome Atlas (TCGA) cohorts.
|
|
|
| ||||
|
|
|
|
|
|
| |
| Age | 1.3543 | 0.8405-2.1821 | 0.2126 | - | - | - |
| Gender | 1.114 | 0.7309-1.6993 | 0.6143 | - | - | - |
| Tumor Grade | 1.3772 | 1.0200-1.8594 | 0.0366 | 1.2353 | 0.8949-1.7051 | 0.1988 |
| Clinical Stage | 1.4221 | 0.9787-2.0663 | 0.0646 | - | - | - |
| ITPR1 | 0.8443 | 0.7239-0.9847 | 0.0310 | 0.8889 | 0.7570-1.0437 | 0.1506 |
| ITPR2 | 0.9719 | 0.9080-1.0404 | 0.4131 | - | - | - |
| ITPR3 | 1.0247 | 1.0077-1.0420 | 0.0042 | 1.0186 | 1.0003-1.0372 | 0.0452 |
Figure 4The alterations and immune infiltration of ITPRs in pancreatic cancer. (A) The alterations of ITPRs in pancreatic cancer (cBioPortal database). (B) The immune infiltration of ITPR1. (Timer database). (C) The immune infiltration of ITPR2. (Timer database). (D) The immune infiltration of ITPR3. (Timer database).
Figure 5The methylation status of ITPRs (Wanderer database). (A) The methylation status of ITPR1. (B) The methylation status of ITPR2. (C) The methylation status of ITPR3.
Figure 6The GGI, PPI, and predicted functions analysis of ITPRs. (A) The GGI network of ITPRs (GeneMANIA). (B) The PPI network of ITPRs (String). (C) Predicted functions and pathways of ITPRs. (From left to right ITPR1, ITPR2, ITPR3) (David database).
Figure 7The expression levels of ITPRs in pancreatic cancer samples and cell lines. (A) The expression levels of ITPR1 in pancreatic cancer cell lines. (B) The expression levels of ITPR2 in pancreatic cancer cell lines. (C) The expression levels of ITPR3 in pancreatic cancer cell lines. (D) The expression levels of ITPR1 in pancreatic cancer samples. (E) The expression levels of ITPR2 in pancreatic cancer samples. (F) The expression levels of ITPR3 in pancreatic cancer samples.
Relationship between ITPR3 expression and clinicopathologic characteristics of PAAD patients.
|
|
|
|
| |
|
|
| |||
| Age | 0.299 | |||
| ≤ 65 years | 28 | 10 | 18 | |
| > 65 years | 24 | 12 | 12 | |
| Gender | 0.786 | |||
| Male | 26 | 12 | 14 | |
| Female | 26 | 10 | 16 | |
| Serum CA19-9 level | 0.055 | |||
| >37 U/ml | 38 | 11 | 27 | |
| ≤37 U/ml | 14 | 9 | 5 | |
| Histologic differentiation | 0.101 | |||
| Well | 13 | 8 | 5 | |
| Moderate | 23 | 7 | 16 | |
| Poor | 16 | 10 | 6 | |
| TNM stage | 0.035 | |||
| I-II | 23 | 13 | 10 | |
| III-IV | 29 | 8 | 21 | |
| Lymph node invasion | 0.038 | |||
| Present | 29 | 6 | 23 | |
| Absent | 23 | 11 | 12 | |
Figure 8ITPR3 is required for PAAD cell proliferation, migration, and invasion (A) RT-qPCR analysis was employed to examine the efficiency of ITPR3 knockdown or overexpression in Bxpc3 and PANC1 cells. (B) Proliferation curves were determined in ITPR3 knockdown or overexpressed Bxpc3 and PANC1 cells by cell counting kit-8 (CCK-8) assays. (C) Clonogenic assays measured colony-forming abilities in ITPR3 stable knockdown or overexpressed Bxpc3 and PANC1 cells. (D) Transwell assays were used to detect the migration and invasive capacities in ITPR3 stable knockdown or overexpressed Bxpc3 and PANC1 cells.
Figure 9ITPR3 overexpression induces endoplasmic reticulum stress (ERS) in pancreatic cells.